Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has successfully finalised its acquisition of Amolyt Pharma, a clinical-stage biotechnology firm specialising in novel treatments for rare endocrine diseases. This acquisition strengthens Alexion, AstraZeneca Rare Disease's late-stage pipeline and expands its bone metabolism portfolio with eneboparatide (AZP-3601), a Phase III therapeutic peptide targeting hypoparathyroidism, a condition marked by disrupted calcium and phosphate regulation.
The deal, valued at up to USD1.05bn on a cash and debt-free basis, includes an USD800m upfront payment at closing and a contingent USD250m based on achieving specified regulatory milestones. AstraZeneca anticipates integrating Amolyt Pharma's talent and pipeline to bolster its presence in rare endocrinology.
Eneboparatide (AZP-3601) is designed to bind tightly to the parathyroid hormone receptor, aiming to regulate serum calcium levels, reduce urine calcium excretion and potentially mitigate kidney function decline and bone integrity issues in hypoparathyroidism patients.
AstraZeneca, headquartered in Cambridge, UK, is focussed on Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Operating in over 125 countries, the company's medicines are vital to millions of patients worldwide.
biopharmaceutical leader
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024